| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Approval | 60 | 2022 | 817 | 8.420 |
Why?
|
| Drug Industry | 69 | 2022 | 793 | 7.920 |
Why?
|
| United States Food and Drug Administration | 83 | 2022 | 1669 | 7.430 |
Why?
|
| Prescription Drugs | 29 | 2021 | 634 | 4.370 |
Why?
|
| Drug Costs | 50 | 2022 | 1196 | 4.330 |
Why?
|
| Drugs, Generic | 36 | 2022 | 454 | 4.220 |
Why?
|
| Drug Prescriptions | 64 | 2019 | 1677 | 3.850 |
Why?
|
| Government Regulation | 20 | 2021 | 525 | 3.770 |
Why?
|
| Marketing | 19 | 2017 | 224 | 3.700 |
Why?
|
| Legislation, Drug | 16 | 2022 | 216 | 2.940 |
Why?
|
| Drug Evaluation | 10 | 2020 | 642 | 2.290 |
Why?
|
| Drug Discovery | 12 | 2020 | 1062 | 2.260 |
Why?
|
| Off-Label Use | 9 | 2020 | 186 | 2.200 |
Why?
|
| Drug Labeling | 19 | 2015 | 250 | 2.070 |
Why?
|
| Product Surveillance, Postmarketing | 17 | 2022 | 463 | 2.040 |
Why?
|
| Drug Utilization | 56 | 2016 | 1192 | 1.920 |
Why?
|
| United States | 255 | 2023 | 73121 | 1.910 |
Why?
|
| Antihypertensive Agents | 22 | 2019 | 2028 | 1.860 |
Why?
|
| Patents as Topic | 15 | 2022 | 113 | 1.830 |
Why?
|
| Pharmacoepidemiology | 15 | 2013 | 352 | 1.780 |
Why?
|
| Insurance, Pharmaceutical Services | 20 | 2021 | 348 | 1.740 |
Why?
|
| Medicaid | 45 | 2023 | 2843 | 1.710 |
Why?
|
| Orphan Drug Production | 5 | 2021 | 48 | 1.650 |
Why?
|
| Drug Therapy | 19 | 2012 | 504 | 1.630 |
Why?
|
| Device Approval | 7 | 2021 | 164 | 1.580 |
Why?
|
| Financing, Government | 7 | 2021 | 473 | 1.580 |
Why?
|
| Drug Utilization Review | 18 | 2016 | 248 | 1.500 |
Why?
|
| Drug and Narcotic Control | 7 | 2021 | 146 | 1.490 |
Why?
|
| Cyclooxygenase Inhibitors | 11 | 2007 | 361 | 1.490 |
Why?
|
| Pharmaceutical Preparations | 19 | 2023 | 1089 | 1.470 |
Why?
|
| Patient Compliance | 31 | 2011 | 2696 | 1.450 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 36 | 2018 | 3253 | 1.450 |
Why?
|
| New Jersey | 39 | 2015 | 295 | 1.410 |
Why?
|
| Prescription Fees | 16 | 2022 | 153 | 1.320 |
Why?
|
| Costs and Cost Analysis | 13 | 2023 | 1670 | 1.240 |
Why?
|
| Lactones | 8 | 2012 | 316 | 1.210 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 17 | 2019 | 1518 | 1.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 26 | 2009 | 2279 | 1.150 |
Why?
|
| Health Policy | 24 | 2018 | 2699 | 1.140 |
Why?
|
| Physicians | 24 | 2022 | 4615 | 1.140 |
Why?
|
| Medication Adherence | 21 | 2021 | 2190 | 1.110 |
Why?
|
| Research Design | 31 | 2021 | 6217 | 1.110 |
Why?
|
| Myocardial Infarction | 37 | 2019 | 11515 | 1.100 |
Why?
|
| Humans | 548 | 2023 | 768451 | 1.090 |
Why?
|
| Research Support as Topic | 7 | 2017 | 699 | 1.090 |
Why?
|
| Clinical Trials as Topic | 20 | 2021 | 8051 | 1.080 |
Why?
|
| Comparative Effectiveness Research | 7 | 2017 | 712 | 1.060 |
Why?
|
| Osteoporosis | 21 | 2012 | 1606 | 1.050 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 9 | 2012 | 495 | 1.050 |
Why?
|
| Hypolipidemic Agents | 10 | 2012 | 609 | 1.050 |
Why?
|
| Education, Medical, Continuing | 17 | 2014 | 829 | 1.040 |
Why?
|
| Hypertension | 26 | 2019 | 8611 | 1.030 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 10 | 2012 | 321 | 1.000 |
Why?
|
| Rare Diseases | 4 | 2018 | 630 | 1.000 |
Why?
|
| Antipsychotic Agents | 16 | 2018 | 3077 | 0.980 |
Why?
|
| Viral Vaccines | 2 | 2020 | 596 | 0.970 |
Why?
|
| Nursing Homes | 34 | 2012 | 1084 | 0.970 |
Why?
|
| Aged | 256 | 2021 | 171520 | 0.950 |
Why?
|
| Frail Elderly | 7 | 2019 | 774 | 0.920 |
Why?
|
| National Institutes of Health (U.S.) | 10 | 2020 | 794 | 0.900 |
Why?
|
| Sulfones | 8 | 2012 | 448 | 0.900 |
Why?
|
| Cardiovascular Agents | 9 | 2015 | 849 | 0.890 |
Why?
|
| Cost Savings | 15 | 2020 | 916 | 0.880 |
Why?
|
| Nephrology | 6 | 2007 | 268 | 0.870 |
Why?
|
| Moon | 1 | 2023 | 6 | 0.870 |
Why?
|
| Insurance, Health, Reimbursement | 7 | 2017 | 389 | 0.870 |
Why?
|
| Evidence-Based Medicine | 18 | 2017 | 3708 | 0.870 |
Why?
|
| Aged, 80 and over | 132 | 2021 | 59680 | 0.870 |
Why?
|
| Cost-Benefit Analysis | 40 | 2017 | 5532 | 0.870 |
Why?
|
| Anticoagulants | 17 | 2021 | 4840 | 0.860 |
Why?
|
| Conflict of Interest | 6 | 2015 | 556 | 0.840 |
Why?
|
| Nonprescription Drugs | 5 | 2022 | 119 | 0.830 |
Why?
|
| Medicare Part D | 5 | 2020 | 358 | 0.830 |
Why?
|
| Diffusion of Innovation | 6 | 2013 | 730 | 0.830 |
Why?
|
| Hemophilia A | 9 | 2017 | 359 | 0.830 |
Why?
|
| Kidney Failure, Chronic | 12 | 2011 | 2489 | 0.800 |
Why?
|
| Drug Substitution | 3 | 2022 | 291 | 0.790 |
Why?
|
| Medicare | 38 | 2021 | 6881 | 0.770 |
Why?
|
| Renal Dialysis | 9 | 2011 | 1802 | 0.770 |
Why?
|
| Commerce | 6 | 2023 | 613 | 0.770 |
Why?
|
| Randomized Controlled Trials as Topic | 31 | 2018 | 10358 | 0.760 |
Why?
|
| Civil Rights | 2 | 2015 | 131 | 0.740 |
Why?
|
| Antidepressive Agents | 17 | 2016 | 2913 | 0.740 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2021 | 49 | 0.740 |
Why?
|
| Hyperlipidemias | 4 | 2009 | 773 | 0.710 |
Why?
|
| Patient Education as Topic | 19 | 2012 | 2339 | 0.710 |
Why?
|
| Pennsylvania | 23 | 2011 | 616 | 0.700 |
Why?
|
| Immunization Schedule | 1 | 2021 | 227 | 0.700 |
Why?
|
| Insurance Claim Review | 11 | 2019 | 745 | 0.700 |
Why?
|
| Risk | 28 | 2017 | 9642 | 0.670 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 3116 | 0.670 |
Why?
|
| Liability, Legal | 4 | 2012 | 208 | 0.660 |
Why?
|
| Science | 2 | 2017 | 239 | 0.660 |
Why?
|
| Benzimidazoles | 6 | 2015 | 864 | 0.650 |
Why?
|
| Herpes Zoster | 1 | 2021 | 253 | 0.640 |
Why?
|
| Anticonvulsants | 8 | 2015 | 1923 | 0.640 |
Why?
|
| Hip Fractures | 6 | 2015 | 996 | 0.640 |
Why?
|
| beta-Alanine | 4 | 2014 | 82 | 0.630 |
Why?
|
| Female | 262 | 2022 | 396943 | 0.620 |
Why?
|
| Intellectual Property | 4 | 2021 | 32 | 0.620 |
Why?
|
| Adrenergic beta-Antagonists | 12 | 2014 | 1244 | 0.620 |
Why?
|
| Male | 247 | 2022 | 364781 | 0.610 |
Why?
|
| Simvastatin | 2 | 2012 | 346 | 0.610 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3240 | 0.610 |
Why?
|
| Cohort Studies | 82 | 2022 | 41797 | 0.600 |
Why?
|
| Health Expenditures | 12 | 2018 | 2391 | 0.580 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 8 | 2018 | 429 | 0.580 |
Why?
|
| Drugs, Investigational | 5 | 2020 | 213 | 0.580 |
Why?
|
| Therapeutic Equivalency | 7 | 2017 | 134 | 0.580 |
Why?
|
| Pyridones | 6 | 2021 | 819 | 0.570 |
Why?
|
| Pyrazoles | 11 | 2021 | 2024 | 0.570 |
Why?
|
| Angiotensin Receptor Antagonists | 4 | 2019 | 1066 | 0.560 |
Why?
|
| Drug Repositioning | 2 | 2020 | 244 | 0.560 |
Why?
|
| Persuasive Communication | 2 | 2017 | 58 | 0.550 |
Why?
|
| Factor VIIa | 3 | 2017 | 103 | 0.550 |
Why?
|
| Investments | 2 | 2023 | 149 | 0.550 |
Why?
|
| Warfarin | 12 | 2021 | 1493 | 0.550 |
Why?
|
| Pyridines | 7 | 2021 | 2888 | 0.530 |
Why?
|
| Bone Density Conservation Agents | 8 | 2015 | 797 | 0.530 |
Why?
|
| Capital Financing | 2 | 2021 | 58 | 0.530 |
Why?
|
| Homes for the Aged | 14 | 1999 | 273 | 0.530 |
Why?
|
| History, 20th Century | 14 | 2021 | 2772 | 0.520 |
Why?
|
| Morpholines | 4 | 2014 | 583 | 0.520 |
Why?
|
| Public Sector | 4 | 2021 | 265 | 0.510 |
Why?
|
| Injections, Intramuscular | 1 | 2017 | 557 | 0.510 |
Why?
|
| Treatment Refusal | 7 | 2007 | 432 | 0.510 |
Why?
|
| Atrial Fibrillation | 11 | 2021 | 5162 | 0.510 |
Why?
|
| Dystrophin | 1 | 2016 | 284 | 0.500 |
Why?
|
| Hypoglycemic Agents | 12 | 2022 | 3111 | 0.490 |
Why?
|
| Antidepressive Agents, Tricyclic | 4 | 2014 | 433 | 0.490 |
Why?
|
| Supreme Court Decisions | 3 | 2013 | 135 | 0.480 |
Why?
|
| Quinolines | 3 | 2017 | 769 | 0.480 |
Why?
|
| Thiophenes | 4 | 2014 | 570 | 0.480 |
Why?
|
| Benzothiadiazines | 5 | 2001 | 31 | 0.470 |
Why?
|
| Azetidines | 2 | 2012 | 143 | 0.470 |
Why?
|
| Muscular Dystrophies | 1 | 2017 | 394 | 0.470 |
Why?
|
| Psychomotor Performance | 1 | 2023 | 1894 | 0.470 |
Why?
|
| Disclosure | 4 | 2021 | 750 | 0.470 |
Why?
|
| Influenza Vaccines | 2 | 2021 | 781 | 0.460 |
Why?
|
| Organizations, Nonprofit | 3 | 2017 | 105 | 0.460 |
Why?
|
| Polypharmacy | 6 | 2012 | 307 | 0.460 |
Why?
|
| Inappropriate Prescribing | 1 | 2017 | 212 | 0.460 |
Why?
|
| Biological Products | 5 | 2021 | 937 | 0.460 |
Why?
|
| Sulfonamides | 5 | 2015 | 1988 | 0.460 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 5 | 2001 | 78 | 0.450 |
Why?
|
| Coronary Artery Bypass | 5 | 2007 | 2194 | 0.450 |
Why?
|
| Methylergonovine | 1 | 2013 | 8 | 0.450 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2016 | 271 | 0.450 |
Why?
|
| Physicians, Family | 6 | 2009 | 349 | 0.440 |
Why?
|
| Plasma Substitutes | 2 | 2003 | 58 | 0.440 |
Why?
|
| Hydrochlorothiazide | 2 | 2009 | 95 | 0.440 |
Why?
|
| Epinephrine | 1 | 2017 | 795 | 0.440 |
Why?
|
| Pandemics | 5 | 2021 | 8753 | 0.430 |
Why?
|
| Logistic Models | 38 | 2015 | 13324 | 0.430 |
Why?
|
| Cardiovascular Diseases | 21 | 2018 | 15638 | 0.430 |
Why?
|
| History, 21st Century | 9 | 2021 | 1575 | 0.430 |
Why?
|
| Cholinergic Antagonists | 6 | 2002 | 167 | 0.430 |
Why?
|
| Anti-Ulcer Agents | 4 | 2010 | 112 | 0.420 |
Why?
|
| Depressive Disorder | 10 | 2014 | 3738 | 0.420 |
Why?
|
| Analgesics, Opioid | 7 | 2022 | 3837 | 0.420 |
Why?
|
| Oxytocics | 1 | 2013 | 67 | 0.420 |
Why?
|
| Anticholesteremic Agents | 7 | 2017 | 972 | 0.420 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2015 | 341 | 0.410 |
Why?
|
| Patient Participation | 5 | 2015 | 1450 | 0.410 |
Why?
|
| Referral and Consultation | 6 | 2010 | 3629 | 0.410 |
Why?
|
| Comorbidity | 20 | 2018 | 10601 | 0.400 |
Why?
|
| Middle Aged | 126 | 2021 | 223418 | 0.400 |
Why?
|
| Influenza, Human | 2 | 2021 | 1540 | 0.400 |
Why?
|
| Insurance Claim Reporting | 5 | 2007 | 166 | 0.400 |
Why?
|
| Nebulizers and Vaporizers | 3 | 2022 | 139 | 0.400 |
Why?
|
| Risk Assessment | 28 | 2021 | 24311 | 0.400 |
Why?
|
| Complementary Therapies | 2 | 2015 | 487 | 0.390 |
Why?
|
| Peptic Ulcer | 3 | 2009 | 222 | 0.390 |
Why?
|
| Health Services Research | 12 | 2016 | 1815 | 0.380 |
Why?
|
| Communication | 10 | 2022 | 3910 | 0.380 |
Why?
|
| Kidney Diseases | 5 | 2007 | 2102 | 0.380 |
Why?
|
| Databases, Factual | 18 | 2021 | 8081 | 0.380 |
Why?
|
| Cost Control | 10 | 2021 | 627 | 0.370 |
Why?
|
| Medication Systems, Hospital | 4 | 2005 | 154 | 0.370 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2011 | 140 | 0.360 |
Why?
|
| Peritoneal Dialysis | 2 | 2002 | 160 | 0.360 |
Why?
|
| Dietary Supplements | 3 | 2022 | 3445 | 0.360 |
Why?
|
| Quality Assurance, Health Care | 8 | 2010 | 2179 | 0.360 |
Why?
|
| Diphosphonates | 2 | 2015 | 635 | 0.360 |
Why?
|
| Clozapine | 4 | 2007 | 508 | 0.360 |
Why?
|
| Thalidomide | 2 | 2016 | 885 | 0.360 |
Why?
|
| Physician-Patient Relations | 8 | 2018 | 3267 | 0.360 |
Why?
|
| Ticlopidine | 4 | 2012 | 730 | 0.360 |
Why?
|
| Thiazides | 1 | 2010 | 19 | 0.350 |
Why?
|
| Hypnotics and Sedatives | 7 | 2017 | 1188 | 0.350 |
Why?
|
| Hospitalization | 23 | 2015 | 10845 | 0.350 |
Why?
|
| Patient Discharge | 5 | 2018 | 3471 | 0.350 |
Why?
|
| Bacteriuria | 3 | 1996 | 102 | 0.350 |
Why?
|
| Arthritis, Rheumatoid | 14 | 2008 | 3763 | 0.350 |
Why?
|
| Risk Factors | 65 | 2018 | 74915 | 0.350 |
Why?
|
| Lipoproteins, HDL | 2 | 2012 | 682 | 0.350 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2013 | 2768 | 0.350 |
Why?
|
| Amines | 1 | 2011 | 280 | 0.340 |
Why?
|
| Economic Competition | 6 | 2018 | 223 | 0.340 |
Why?
|
| Lipoproteins, LDL | 2 | 2012 | 644 | 0.340 |
Why?
|
| Authorship | 2 | 2012 | 287 | 0.340 |
Why?
|
| Blood Coagulation Factors | 3 | 2017 | 366 | 0.340 |
Why?
|
| Data Collection | 6 | 2013 | 3329 | 0.340 |
Why?
|
| Time Factors | 30 | 2021 | 40271 | 0.340 |
Why?
|
| Decision Support Systems, Clinical | 4 | 2008 | 1176 | 0.340 |
Why?
|
| Osteoporotic Fractures | 1 | 2015 | 417 | 0.340 |
Why?
|
| Angina, Unstable | 3 | 2003 | 893 | 0.340 |
Why?
|
| Politics | 5 | 2020 | 821 | 0.340 |
Why?
|
| Consumer Product Safety | 5 | 2022 | 122 | 0.340 |
Why?
|
| Deductibles and Coinsurance | 5 | 2021 | 316 | 0.340 |
Why?
|
| Antirheumatic Agents | 10 | 2008 | 1374 | 0.340 |
Why?
|
| Epidemiologic Methods | 11 | 2012 | 1337 | 0.330 |
Why?
|
| Health Services for the Aged | 5 | 2007 | 258 | 0.330 |
Why?
|
| Postpartum Hemorrhage | 1 | 2013 | 273 | 0.330 |
Why?
|
| Cost Sharing | 8 | 2015 | 409 | 0.330 |
Why?
|
| Retrospective Studies | 58 | 2023 | 81834 | 0.330 |
Why?
|
| Postoperative Hemorrhage | 2 | 2003 | 420 | 0.330 |
Why?
|
| Bibliometrics | 2 | 2013 | 354 | 0.330 |
Why?
|
| Erythropoietin | 3 | 2011 | 719 | 0.320 |
Why?
|
| Bronchodilator Agents | 2 | 2022 | 519 | 0.320 |
Why?
|
| Isoenzymes | 3 | 2004 | 1685 | 0.320 |
Why?
|
| Insurance, Health | 6 | 2018 | 2513 | 0.320 |
Why?
|
| Education, Medical | 7 | 2015 | 1742 | 0.320 |
Why?
|
| Fluorobenzenes | 1 | 2011 | 179 | 0.320 |
Why?
|
| Digoxin | 3 | 2004 | 246 | 0.320 |
Why?
|
| Quality Indicators, Health Care | 4 | 2012 | 1813 | 0.320 |
Why?
|
| Embolism | 1 | 2012 | 401 | 0.320 |
Why?
|
| Sample Size | 5 | 2021 | 851 | 0.310 |
Why?
|
| Multivariate Analysis | 21 | 2016 | 12096 | 0.310 |
Why?
|
| Case-Control Studies | 26 | 2014 | 22293 | 0.310 |
Why?
|
| Hemostatics | 1 | 2011 | 246 | 0.300 |
Why?
|
| Propranolol | 1 | 2010 | 493 | 0.300 |
Why?
|
| Mortality | 10 | 2012 | 2917 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 10 | 2019 | 4049 | 0.300 |
Why?
|
| Industry | 1 | 2010 | 366 | 0.300 |
Why?
|
| Benzodiazepines | 8 | 2017 | 1139 | 0.290 |
Why?
|
| Reminder Systems | 3 | 2014 | 386 | 0.290 |
Why?
|
| Insurance Coverage | 6 | 2022 | 1946 | 0.290 |
Why?
|
| Hip Prosthesis | 1 | 2013 | 924 | 0.290 |
Why?
|
| Computer Communication Networks | 1 | 2009 | 295 | 0.290 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2017 | 10784 | 0.290 |
Why?
|
| Propensity Score | 10 | 2015 | 1971 | 0.290 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2009 | 490 | 0.280 |
Why?
|
| Policy Making | 5 | 2020 | 545 | 0.280 |
Why?
|
| Coronary Disease | 8 | 2013 | 5926 | 0.280 |
Why?
|
| Research Subjects | 3 | 2009 | 249 | 0.280 |
Why?
|
| Managed Care Programs | 6 | 2017 | 941 | 0.280 |
Why?
|
| Drug Contamination | 1 | 2008 | 152 | 0.280 |
Why?
|
| British Columbia | 9 | 2010 | 241 | 0.280 |
Why?
|
| Investigational New Drug Application | 3 | 2018 | 5 | 0.280 |
Why?
|
| Academic Medical Centers | 6 | 2015 | 2785 | 0.280 |
Why?
|
| Odds Ratio | 23 | 2014 | 9687 | 0.270 |
Why?
|
| Information Dissemination | 5 | 2021 | 1138 | 0.270 |
Why?
|
| Parkinson Disease, Secondary | 3 | 1995 | 122 | 0.270 |
Why?
|
| Hydroxychloroquine | 2 | 2021 | 427 | 0.270 |
Why?
|
| Aprotinin | 1 | 2006 | 94 | 0.270 |
Why?
|
| Administration, Oral | 12 | 2014 | 4041 | 0.270 |
Why?
|
| Health Communication | 2 | 2019 | 216 | 0.270 |
Why?
|
| Hemorrhage | 6 | 2013 | 3458 | 0.270 |
Why?
|
| Consumer Health Information | 1 | 2009 | 215 | 0.270 |
Why?
|
| Natriuretic Agents | 1 | 2006 | 57 | 0.270 |
Why?
|
| Basal Ganglia Diseases | 3 | 1995 | 145 | 0.260 |
Why?
|
| Diuretics | 8 | 2009 | 612 | 0.260 |
Why?
|
| Hypercholesterolemia | 5 | 2018 | 1142 | 0.260 |
Why?
|
| Publication Bias | 1 | 2006 | 160 | 0.260 |
Why?
|
| Factor VIII | 7 | 2005 | 349 | 0.260 |
Why?
|
| Pregnancy Complications | 3 | 2014 | 2969 | 0.260 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2007 | 373 | 0.260 |
Why?
|
| Adult | 89 | 2019 | 223542 | 0.260 |
Why?
|
| Heparin | 3 | 2008 | 1636 | 0.260 |
Why?
|
| Cerebrovascular Disorders | 3 | 1997 | 1487 | 0.260 |
Why?
|
| Cross-Sectional Studies | 27 | 2023 | 26351 | 0.260 |
Why?
|
| Drug Monitoring | 6 | 2021 | 964 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 14 | 2014 | 7451 | 0.250 |
Why?
|
| Psychotropic Drugs | 8 | 2005 | 888 | 0.250 |
Why?
|
| Stroke | 10 | 2021 | 9791 | 0.250 |
Why?
|
| Omeprazole | 1 | 2006 | 106 | 0.250 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 2188 | 0.250 |
Why?
|
| Muscular Diseases | 1 | 2010 | 555 | 0.250 |
Why?
|
| Regression Analysis | 14 | 2012 | 6353 | 0.250 |
Why?
|
| Age Factors | 30 | 2016 | 18478 | 0.250 |
Why?
|
| Coronary Artery Disease | 5 | 2014 | 6551 | 0.250 |
Why?
|
| Hemarthrosis | 1 | 2005 | 39 | 0.250 |
Why?
|
| Budgets | 2 | 2017 | 232 | 0.250 |
Why?
|
| Treatment Outcome | 37 | 2018 | 65409 | 0.250 |
Why?
|
| Medication Systems | 1 | 2005 | 31 | 0.250 |
Why?
|
| Quality Improvement | 2 | 2019 | 3858 | 0.250 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2011 | 1140 | 0.250 |
Why?
|
| Pharmacy | 2 | 2022 | 92 | 0.250 |
Why?
|
| Technology Transfer | 1 | 2005 | 42 | 0.240 |
Why?
|
| Cost of Illness | 6 | 2017 | 1960 | 0.240 |
Why?
|
| Pharmaceutical Services | 3 | 2007 | 143 | 0.240 |
Why?
|
| Medical Assistance | 2 | 2012 | 108 | 0.240 |
Why?
|
| Marketing of Health Services | 2 | 2017 | 151 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 9 | 2016 | 7471 | 0.240 |
Why?
|
| Stents | 2 | 2014 | 3204 | 0.240 |
Why?
|
| Drug Interactions | 9 | 2013 | 1421 | 0.240 |
Why?
|
| Diabetes Mellitus | 8 | 2015 | 5887 | 0.240 |
Why?
|
| Angioplasty, Balloon, Coronary | 3 | 2014 | 1724 | 0.240 |
Why?
|
| Health Care Costs | 9 | 2015 | 3265 | 0.240 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2013 | 938 | 0.240 |
Why?
|
| Fractures, Spontaneous | 4 | 2007 | 232 | 0.240 |
Why?
|
| Pravastatin | 2 | 2006 | 393 | 0.240 |
Why?
|
| Iatrogenic Disease | 1 | 2008 | 552 | 0.240 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2004 | 1166 | 0.240 |
Why?
|
| Geriatrics | 3 | 2005 | 390 | 0.240 |
Why?
|
| Research | 6 | 2021 | 1984 | 0.240 |
Why?
|
| Immunosuppressive Agents | 4 | 2016 | 4213 | 0.240 |
Why?
|
| Activities of Daily Living | 4 | 2019 | 2433 | 0.230 |
Why?
|
| Models, Economic | 5 | 2015 | 717 | 0.230 |
Why?
|
| Electric Stimulation Therapy | 1 | 2010 | 636 | 0.230 |
Why?
|
| Health Services Accessibility | 4 | 2020 | 5510 | 0.230 |
Why?
|
| Antitubercular Agents | 1 | 2013 | 1390 | 0.230 |
Why?
|
| Venous Thrombosis | 3 | 2017 | 1318 | 0.230 |
Why?
|
| Economics, Pharmaceutical | 2 | 2004 | 88 | 0.230 |
Why?
|
| Kidney | 4 | 2006 | 7064 | 0.230 |
Why?
|
| Epilepsy | 4 | 2015 | 3324 | 0.230 |
Why?
|
| Students, Medical | 6 | 2015 | 1962 | 0.230 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2008 | 775 | 0.230 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 5426 | 0.230 |
Why?
|
| Fees, Pharmaceutical | 5 | 2016 | 66 | 0.220 |
Why?
|
| Health Care Sector | 1 | 2006 | 196 | 0.220 |
Why?
|
| Parasympatholytics | 2 | 2002 | 89 | 0.220 |
Why?
|
| Protein C | 1 | 2004 | 134 | 0.220 |
Why?
|
| Glaucoma | 5 | 2011 | 1193 | 0.220 |
Why?
|
| Patient Selection | 8 | 2008 | 4266 | 0.220 |
Why?
|
| Endpoint Determination | 3 | 2017 | 591 | 0.220 |
Why?
|
| Cardiology | 2 | 2014 | 1701 | 0.220 |
Why?
|
| Markov Chains | 9 | 2015 | 977 | 0.220 |
Why?
|
| Antifibrinolytic Agents | 1 | 2006 | 289 | 0.220 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2018 | 3682 | 0.210 |
Why?
|
| Heptanoic Acids | 1 | 2005 | 344 | 0.210 |
Why?
|
| Decision Making | 14 | 2022 | 3961 | 0.210 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2013 | 1418 | 0.210 |
Why?
|
| Public Health | 4 | 2020 | 2693 | 0.210 |
Why?
|
| Attitude of Health Personnel | 11 | 2015 | 3922 | 0.210 |
Why?
|
| Biotechnology | 1 | 2005 | 282 | 0.210 |
Why?
|
| Plant Preparations | 1 | 2003 | 94 | 0.210 |
Why?
|
| Acute Coronary Syndrome | 2 | 2013 | 2195 | 0.210 |
Why?
|
| Direct Service Costs | 1 | 2002 | 61 | 0.210 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2009 | 1568 | 0.210 |
Why?
|
| Intraoperative Care | 2 | 2003 | 772 | 0.210 |
Why?
|
| Dopamine Agonists | 1 | 2005 | 353 | 0.210 |
Why?
|
| Health Services Misuse | 4 | 2003 | 249 | 0.200 |
Why?
|
| Interprofessional Relations | 5 | 2017 | 997 | 0.200 |
Why?
|
| Thrombolytic Therapy | 3 | 2004 | 2058 | 0.200 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2012 | 792 | 0.200 |
Why?
|
| Confidentiality | 3 | 2015 | 606 | 0.200 |
Why?
|
| Legislation, Food | 1 | 2022 | 17 | 0.200 |
Why?
|
| Medication Errors | 4 | 2009 | 783 | 0.200 |
Why?
|
| Geriatric Assessment | 4 | 2019 | 1422 | 0.200 |
Why?
|
| Aging | 8 | 2001 | 8761 | 0.200 |
Why?
|
| Glaucoma, Open-Angle | 2 | 2000 | 742 | 0.200 |
Why?
|
| Quality-Adjusted Life Years | 9 | 2013 | 1734 | 0.200 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2003 | 197 | 0.200 |
Why?
|
| Miotics | 2 | 2000 | 9 | 0.200 |
Why?
|
| Secondary Prevention | 5 | 2015 | 1479 | 0.200 |
Why?
|
| Hospital Departments | 1 | 2002 | 135 | 0.200 |
Why?
|
| Health Maintenance Organizations | 3 | 2004 | 658 | 0.200 |
Why?
|
| Narcotics | 1 | 2004 | 337 | 0.200 |
Why?
|
| Phosphorus | 1 | 2003 | 336 | 0.190 |
Why?
|
| Kidney Function Tests | 4 | 2007 | 681 | 0.190 |
Why?
|
| Dopamine Antagonists | 1 | 2002 | 289 | 0.190 |
Why?
|
| Drug Packaging | 2 | 2014 | 44 | 0.190 |
Why?
|
| Preventive Health Services | 2 | 2007 | 568 | 0.190 |
Why?
|
| Proportional Hazards Models | 16 | 2016 | 12561 | 0.190 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2005 | 277 | 0.190 |
Why?
|
| Periodicals as Topic | 2 | 2012 | 1468 | 0.190 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2017 | 113 | 0.190 |
Why?
|
| Hyperparathyroidism | 1 | 2003 | 339 | 0.190 |
Why?
|
| Internal Medicine | 3 | 2019 | 1056 | 0.190 |
Why?
|
| Insulin | 4 | 2016 | 6606 | 0.190 |
Why?
|
| Accidental Falls | 5 | 2008 | 1081 | 0.190 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 4984 | 0.190 |
Why?
|
| Drug Therapy, Combination | 14 | 2015 | 6320 | 0.190 |
Why?
|
| Heart Failure | 8 | 2008 | 11857 | 0.190 |
Why?
|
| Knee | 1 | 2003 | 279 | 0.190 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 2396 | 0.190 |
Why?
|
| Muscarinic Antagonists | 1 | 2002 | 135 | 0.190 |
Why?
|
| Hospitals | 4 | 2011 | 3906 | 0.190 |
Why?
|
| Chronic Disease | 12 | 2014 | 9382 | 0.180 |
Why?
|
| Ciprofloxacin | 2 | 2012 | 313 | 0.180 |
Why?
|
| Kidney Transplantation | 3 | 2007 | 4285 | 0.180 |
Why?
|
| Inpatients | 3 | 2007 | 2561 | 0.180 |
Why?
|
| Choice Behavior | 2 | 2019 | 846 | 0.180 |
Why?
|
| Bone Density | 5 | 2008 | 3561 | 0.180 |
Why?
|
| Thiazolidinediones | 4 | 2014 | 462 | 0.180 |
Why?
|
| Statistics as Topic | 4 | 2018 | 2362 | 0.180 |
Why?
|
| Health Services Needs and Demand | 3 | 2020 | 1408 | 0.180 |
Why?
|
| Social Control, Formal | 2 | 2021 | 107 | 0.180 |
Why?
|
| Heart Defects, Congenital | 2 | 2014 | 4713 | 0.180 |
Why?
|
| C-Reactive Protein | 2 | 2011 | 3854 | 0.180 |
Why?
|
| Guideline Adherence | 6 | 2014 | 2239 | 0.180 |
Why?
|
| Quality of Health Care | 7 | 2012 | 4340 | 0.180 |
Why?
|
| Confidence Intervals | 8 | 2014 | 2932 | 0.180 |
Why?
|
| Health Benefit Plans, Employee | 2 | 2015 | 332 | 0.180 |
Why?
|
| Pharmacies | 3 | 2015 | 171 | 0.180 |
Why?
|
| Pulmonary Embolism | 3 | 2017 | 2591 | 0.180 |
Why?
|
| Antiparkinson Agents | 2 | 2005 | 184 | 0.180 |
Why?
|
| Patient Admission | 4 | 2004 | 1370 | 0.170 |
Why?
|
| Sex Distribution | 8 | 2016 | 2286 | 0.170 |
Why?
|
| Advisory Committees | 3 | 2016 | 797 | 0.170 |
Why?
|
| Medical Records | 7 | 2005 | 1413 | 0.170 |
Why?
|
| Antifungal Agents | 1 | 2005 | 761 | 0.170 |
Why?
|
| Renal Replacement Therapy | 1 | 2002 | 283 | 0.170 |
Why?
|
| Internship and Residency | 6 | 2022 | 5952 | 0.170 |
Why?
|
| Hepatitis C, Chronic | 2 | 2020 | 1031 | 0.170 |
Why?
|
| Death, Sudden | 1 | 2002 | 301 | 0.170 |
Why?
|
| Models, Econometric | 3 | 2009 | 215 | 0.170 |
Why?
|
| Public Opinion | 2 | 2019 | 487 | 0.170 |
Why?
|
| Central Nervous System Diseases | 1 | 2004 | 521 | 0.170 |
Why?
|
| Medical Order Entry Systems | 2 | 2007 | 522 | 0.170 |
Why?
|
| Vascular Diseases | 1 | 2008 | 1162 | 0.160 |
Why?
|
| Follow-Up Studies | 25 | 2018 | 39430 | 0.160 |
Why?
|
| Sentinel Surveillance | 2 | 2013 | 292 | 0.160 |
Why?
|
| Decision Support Techniques | 6 | 2009 | 2010 | 0.160 |
Why?
|
| Alzheimer Disease | 3 | 2022 | 8721 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2017 | 3237 | 0.160 |
Why?
|
| Fruit | 2 | 1996 | 1165 | 0.160 |
Why?
|
| Patient Preference | 2 | 2019 | 948 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 13589 | 0.160 |
Why?
|
| Depression | 5 | 2007 | 8235 | 0.160 |
Why?
|
| Osteoarthritis | 5 | 2006 | 1070 | 0.160 |
Why?
|
| Medicare Part B | 2 | 2012 | 117 | 0.160 |
Why?
|
| Health Care Reform | 5 | 2018 | 1256 | 0.160 |
Why?
|
| Patient-Centered Care | 3 | 2014 | 1439 | 0.160 |
Why?
|
| Smoking | 5 | 2016 | 9099 | 0.160 |
Why?
|
| Financial Management | 1 | 2020 | 161 | 0.160 |
Why?
|
| Pyrroles | 1 | 2005 | 1127 | 0.160 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 233 | 0.160 |
Why?
|
| State Medicine | 1 | 2020 | 217 | 0.160 |
Why?
|
| Information Systems | 2 | 1999 | 397 | 0.160 |
Why?
|
| Bioethical Issues | 2 | 2015 | 120 | 0.160 |
Why?
|
| Chloroquine | 1 | 2020 | 275 | 0.160 |
Why?
|
| Delivery of Health Care | 6 | 2022 | 5367 | 0.150 |
Why?
|
| Pyrimidines | 1 | 2011 | 3050 | 0.150 |
Why?
|
| Pharmacy Service, Hospital | 4 | 2002 | 134 | 0.150 |
Why?
|
| Altitude | 2 | 2011 | 164 | 0.150 |
Why?
|
| Long-Term Care | 6 | 2001 | 633 | 0.150 |
Why?
|
| Socioeconomic Factors | 14 | 2016 | 7863 | 0.150 |
Why?
|
| Home Nursing | 1 | 1998 | 92 | 0.150 |
Why?
|
| Breast Neoplasms | 6 | 2006 | 21156 | 0.150 |
Why?
|
| Gift Giving | 2 | 2015 | 76 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2006 | 1891 | 0.150 |
Why?
|
| Incidence | 16 | 2017 | 21552 | 0.150 |
Why?
|
| Tamoxifen | 1 | 2003 | 968 | 0.150 |
Why?
|
| Thrombosis | 1 | 2012 | 2956 | 0.150 |
Why?
|
| Mass Screening | 8 | 2007 | 5455 | 0.150 |
Why?
|
| Lobbying | 1 | 2018 | 32 | 0.150 |
Why?
|
| Gastrointestinal Agents | 1 | 2003 | 510 | 0.150 |
Why?
|
| Phentermine | 1 | 1997 | 31 | 0.150 |
Why?
|
| Coronary Angiography | 3 | 2007 | 4526 | 0.150 |
Why?
|
| Pyuria | 2 | 1995 | 30 | 0.150 |
Why?
|
| Ownership | 1 | 2020 | 343 | 0.150 |
Why?
|
| Enalapril | 1 | 1999 | 316 | 0.150 |
Why?
|
| Drug Combinations | 3 | 2012 | 2079 | 0.150 |
Why?
|
| Fenfluramine | 1 | 1997 | 58 | 0.150 |
Why?
|
| Alanine | 1 | 2020 | 613 | 0.150 |
Why?
|
| Dopamine Agents | 2 | 1995 | 190 | 0.150 |
Why?
|
| Medical Staff, Hospital | 5 | 2007 | 603 | 0.140 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2006 | 1751 | 0.140 |
Why?
|
| Risk Management | 2 | 2015 | 558 | 0.140 |
Why?
|
| Longitudinal Studies | 9 | 2019 | 14766 | 0.140 |
Why?
|
| Urinary Incontinence | 1 | 2002 | 494 | 0.140 |
Why?
|
| Ramipril | 1 | 2018 | 102 | 0.140 |
Why?
|
| Drug Administration Schedule | 10 | 2014 | 4861 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 2702 | 0.140 |
Why?
|
| Research Personnel | 2 | 2015 | 591 | 0.140 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2012 | 1126 | 0.140 |
Why?
|
| Hemophilia B | 1 | 2017 | 83 | 0.140 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2022 | 578 | 0.140 |
Why?
|
| Spain | 2 | 2016 | 491 | 0.140 |
Why?
|
| Appetite Depressants | 1 | 1997 | 108 | 0.140 |
Why?
|
| Patients | 4 | 2010 | 909 | 0.140 |
Why?
|
| Dexfenfluramine | 2 | 2007 | 8 | 0.140 |
Why?
|
| Trust | 2 | 2016 | 532 | 0.140 |
Why?
|
| Legislation as Topic | 1 | 2017 | 76 | 0.140 |
Why?
|
| Risk Adjustment | 5 | 2011 | 603 | 0.140 |
Why?
|
| Europe | 3 | 2011 | 3439 | 0.140 |
Why?
|
| Reproducibility of Results | 11 | 2017 | 20231 | 0.130 |
Why?
|
| Age Distribution | 8 | 2016 | 2881 | 0.130 |
Why?
|
| Ophthalmic Solutions | 2 | 2000 | 315 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2007 | 2258 | 0.130 |
Why?
|
| Codon, Terminator | 1 | 2016 | 125 | 0.130 |
Why?
|
| Risk Reduction Behavior | 2 | 2014 | 1120 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 3 | 2005 | 1207 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 3 | 2010 | 552 | 0.130 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2017 | 162 | 0.130 |
Why?
|
| Netherlands | 7 | 2008 | 2274 | 0.130 |
Why?
|
| Republic of Korea | 2 | 2016 | 587 | 0.130 |
Why?
|
| Immunization | 1 | 2020 | 1220 | 0.130 |
Why?
|
| Massachusetts | 15 | 2021 | 8908 | 0.130 |
Why?
|
| Negotiating | 2 | 2016 | 152 | 0.130 |
Why?
|
| Medical Audit | 6 | 2007 | 454 | 0.130 |
Why?
|
| Metoclopramide | 1 | 1995 | 51 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2022 | 12242 | 0.130 |
Why?
|
| Drug Information Services | 7 | 1996 | 51 | 0.130 |
Why?
|
| Gout | 2 | 2007 | 621 | 0.130 |
Why?
|
| Movement | 1 | 2023 | 1489 | 0.130 |
Why?
|
| Predictive Value of Tests | 13 | 2017 | 15460 | 0.130 |
Why?
|
| Anemia | 3 | 2011 | 1521 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2018 | 15880 | 0.130 |
Why?
|
| Extrapyramidal Tracts | 1 | 1995 | 17 | 0.130 |
Why?
|
| Bacterial Infections | 3 | 2016 | 1397 | 0.130 |
Why?
|
| Dyspepsia | 1 | 1997 | 116 | 0.130 |
Why?
|
| Rheumatic Diseases | 1 | 2003 | 664 | 0.130 |
Why?
|
| State Government | 2 | 2016 | 389 | 0.130 |
Why?
|
| Capital Expenditures | 1 | 2015 | 27 | 0.130 |
Why?
|
| Health Status | 2 | 2006 | 4096 | 0.130 |
Why?
|
| Epidemiologic Research Design | 2 | 2012 | 368 | 0.130 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 1999 | 304 | 0.130 |
Why?
|
| Pain, Postoperative | 2 | 2016 | 1763 | 0.120 |
Why?
|
| Thiazoles | 3 | 2021 | 1541 | 0.120 |
Why?
|
| Histamine H2 Antagonists | 1 | 1997 | 169 | 0.120 |
Why?
|
| Administration, Inhalation | 3 | 2022 | 1170 | 0.120 |
Why?
|
| Observation | 2 | 2007 | 311 | 0.120 |
Why?
|
| Freedom | 1 | 2015 | 69 | 0.120 |
Why?
|
| Ambulatory Care Facilities | 1 | 2001 | 941 | 0.120 |
Why?
|
| Streptokinase | 1 | 1995 | 186 | 0.120 |
Why?
|
| Health Status Indicators | 2 | 2019 | 971 | 0.120 |
Why?
|
| Pulmonary Surfactants | 1 | 1996 | 169 | 0.120 |
Why?
|
| Contraceptives, Oral | 2 | 2016 | 562 | 0.120 |
Why?
|
| Levodopa | 1 | 1995 | 223 | 0.120 |
Why?
|
| Patient Simulation | 1 | 2017 | 297 | 0.120 |
Why?
|
| Hematocrit | 4 | 2011 | 625 | 0.120 |
Why?
|
| Epidemiology | 2 | 2003 | 280 | 0.120 |
Why?
|
| Adolescent | 31 | 2017 | 89168 | 0.120 |
Why?
|
| Glucocorticoids | 6 | 2008 | 2170 | 0.120 |
Why?
|
| Travel | 2 | 2017 | 800 | 0.120 |
Why?
|
| Tooth Extraction | 1 | 2016 | 229 | 0.120 |
Why?
|
| Fibrinolytic Agents | 1 | 2004 | 2082 | 0.120 |
Why?
|
| Algorithms | 6 | 2017 | 14158 | 0.120 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2015 | 262 | 0.120 |
Why?
|
| Antiviral Agents | 3 | 2020 | 3063 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 1536 | 0.120 |
Why?
|
| Ibuprofen | 1 | 1996 | 229 | 0.120 |
Why?
|
| Young Adult | 21 | 2017 | 60045 | 0.110 |
Why?
|
| Sex Factors | 11 | 2014 | 10647 | 0.110 |
Why?
|
| Private Sector | 3 | 2023 | 395 | 0.110 |
Why?
|
| Database Management Systems | 2 | 2008 | 256 | 0.110 |
Why?
|
| Asthma | 4 | 2022 | 6274 | 0.110 |
Why?
|
| Pharmacists | 5 | 2007 | 261 | 0.110 |
Why?
|
| Blood Donors | 7 | 1993 | 345 | 0.110 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 13708 | 0.110 |
Why?
|
| Fluconazole | 2 | 2005 | 156 | 0.110 |
Why?
|
| Lipids | 2 | 2017 | 3346 | 0.110 |
Why?
|
| Safety-Based Drug Withdrawals | 2 | 2013 | 36 | 0.110 |
Why?
|
| Oseltamivir | 1 | 2014 | 75 | 0.110 |
Why?
|
| Health Behavior | 4 | 2011 | 2649 | 0.110 |
Why?
|
| Acetaminophen | 1 | 1998 | 556 | 0.110 |
Why?
|
| Intraocular Pressure | 1 | 2000 | 1304 | 0.110 |
Why?
|
| American Medical Association | 2 | 2011 | 60 | 0.110 |
Why?
|
| Drug Synergism | 2 | 2010 | 1765 | 0.110 |
Why?
|
| Canada | 4 | 2017 | 2143 | 0.110 |
Why?
|
| Communication Barriers | 1 | 2017 | 419 | 0.110 |
Why?
|
| Random Allocation | 5 | 2004 | 2399 | 0.110 |
Why?
|
| Skilled Nursing Facilities | 2 | 1997 | 406 | 0.110 |
Why?
|
| Nursing Staff | 2 | 1991 | 113 | 0.110 |
Why?
|
| Biomedical Research | 3 | 2005 | 3463 | 0.110 |
Why?
|
| Internet | 2 | 2017 | 3123 | 0.110 |
Why?
|
| Benzoates | 1 | 2014 | 213 | 0.110 |
Why?
|
| Length of Stay | 6 | 2008 | 6521 | 0.110 |
Why?
|
| Patient Rights | 1 | 2014 | 127 | 0.110 |
Why?
|
| Telephone | 3 | 2012 | 630 | 0.110 |
Why?
|
| Hydrazines | 1 | 2014 | 223 | 0.110 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2013 | 92 | 0.110 |
Why?
|
| Fractures, Bone | 6 | 2008 | 2063 | 0.110 |
Why?
|
| Self Administration | 4 | 2007 | 387 | 0.110 |
Why?
|
| Sulfanilamides | 1 | 2012 | 14 | 0.100 |
Why?
|
| Ofloxacin | 2 | 2003 | 66 | 0.100 |
Why?
|
| Thrombopoietin | 1 | 2014 | 226 | 0.100 |
Why?
|
| Medicare Part C | 2 | 2021 | 332 | 0.100 |
Why?
|
| Adolescent Psychiatry | 1 | 2014 | 160 | 0.100 |
Why?
|
| Brain Ischemia | 3 | 2013 | 3038 | 0.100 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 318 | 0.100 |
Why?
|
| Evaluation Studies as Topic | 4 | 2008 | 1629 | 0.100 |
Why?
|
| Software | 4 | 2021 | 4463 | 0.100 |
Why?
|
| Qualitative Research | 4 | 2022 | 3115 | 0.100 |
Why?
|
| Vaccines | 1 | 2021 | 845 | 0.100 |
Why?
|
| Prescriptions | 2 | 2020 | 387 | 0.100 |
Why?
|
| Contraception | 1 | 2016 | 362 | 0.100 |
Why?
|
| Naproxen | 2 | 2003 | 101 | 0.100 |
Why?
|
| Lisinopril | 1 | 2012 | 60 | 0.100 |
Why?
|
| Arthritis | 3 | 2008 | 685 | 0.100 |
Why?
|
| Metformin | 3 | 2014 | 914 | 0.100 |
Why?
|
| Survival Analysis | 5 | 2006 | 10125 | 0.100 |
Why?
|
| Schools, Medical | 2 | 2015 | 881 | 0.100 |
Why?
|
| Clindamycin | 2 | 1989 | 139 | 0.100 |
Why?
|
| Ambulatory Care | 3 | 2007 | 2780 | 0.100 |
Why?
|
| Self Care | 3 | 2004 | 798 | 0.100 |
Why?
|
| Blood Pressure | 6 | 2008 | 8538 | 0.100 |
Why?
|
| Fish Oils | 1 | 2015 | 483 | 0.100 |
Why?
|
| Primary Health Care | 5 | 2020 | 4737 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2008 | 4362 | 0.100 |
Why?
|
| Reimbursement, Incentive | 1 | 2017 | 548 | 0.100 |
Why?
|
| Universities | 2 | 2009 | 1007 | 0.090 |
Why?
|
| Paroxetine | 1 | 2012 | 181 | 0.090 |
Why?
|
| Cross-Over Studies | 5 | 2010 | 2103 | 0.090 |
Why?
|
| Cathartics | 4 | 1996 | 129 | 0.090 |
Why?
|
| Parkinson Disease | 1 | 2005 | 2891 | 0.090 |
Why?
|
| Uric Acid | 1 | 1997 | 807 | 0.090 |
Why?
|
| Registries | 4 | 2006 | 8373 | 0.090 |
Why?
|
| Clinical Medicine | 1 | 2012 | 145 | 0.090 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 417 | 0.090 |
Why?
|
| Heart Diseases | 4 | 2015 | 2816 | 0.090 |
Why?
|
| Thromboembolism | 1 | 2017 | 1006 | 0.090 |
Why?
|
| Receptors, Fc | 1 | 2014 | 539 | 0.090 |
Why?
|
| Naphthalenes | 1 | 2012 | 198 | 0.090 |
Why?
|
| Models, Statistical | 10 | 2013 | 5103 | 0.090 |
Why?
|
| Joint Diseases | 2 | 2004 | 460 | 0.090 |
Why?
|
| Income | 2 | 2017 | 1878 | 0.090 |
Why?
|
| Ethylene Glycols | 1 | 2012 | 198 | 0.090 |
Why?
|
| Nurse Practitioners | 2 | 1991 | 271 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 2 | 2004 | 599 | 0.090 |
Why?
|
| Neoplasms | 7 | 2018 | 22386 | 0.090 |
Why?
|
| Exons | 1 | 2016 | 2392 | 0.090 |
Why?
|
| Women | 1 | 1992 | 225 | 0.090 |
Why?
|
| Pregnancy | 8 | 2016 | 30179 | 0.090 |
Why?
|
| International Classification of Diseases | 3 | 2005 | 925 | 0.090 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2014 | 246 | 0.090 |
Why?
|
| Sputum | 1 | 2013 | 511 | 0.090 |
Why?
|
| Constipation | 4 | 1997 | 570 | 0.090 |
Why?
|
| Utilization Review | 3 | 2010 | 384 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 450 | 0.090 |
Why?
|
| Child | 19 | 2017 | 80863 | 0.090 |
Why?
|
| Developed Countries | 1 | 2013 | 451 | 0.090 |
Why?
|
| Iron | 2 | 2010 | 1813 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 6 | 2012 | 2705 | 0.080 |
Why?
|
| Recombinant Proteins | 3 | 2017 | 6527 | 0.080 |
Why?
|
| Calcium | 1 | 2003 | 5793 | 0.080 |
Why?
|
| History, 19th Century | 1 | 2012 | 716 | 0.080 |
Why?
|
| Likelihood Functions | 2 | 2004 | 993 | 0.080 |
Why?
|
| Probability | 2 | 2006 | 2483 | 0.080 |
Why?
|
| Renin-Angiotensin System | 2 | 2012 | 735 | 0.080 |
Why?
|
| Dyslipidemias | 1 | 2017 | 874 | 0.080 |
Why?
|
| Equipment Safety | 1 | 2010 | 250 | 0.080 |
Why?
|
| Sensitivity and Specificity | 8 | 2015 | 14728 | 0.080 |
Why?
|
| Attitude to Health | 4 | 2007 | 2030 | 0.080 |
Why?
|
| Poisson Distribution | 3 | 2013 | 509 | 0.080 |
Why?
|
| International Normalized Ratio | 1 | 2011 | 382 | 0.080 |
Why?
|
| Linear Models | 5 | 2009 | 5880 | 0.080 |
Why?
|
| Healthcare Disparities | 3 | 2014 | 3412 | 0.080 |
Why?
|
| Teaching | 2 | 2011 | 1174 | 0.080 |
Why?
|
| Teaching Materials | 2 | 2005 | 85 | 0.080 |
Why?
|
| Medical Record Linkage | 3 | 2015 | 286 | 0.080 |
Why?
|
| Diagnosis-Related Groups | 3 | 2005 | 448 | 0.080 |
Why?
|
| Motivation | 2 | 2009 | 2034 | 0.080 |
Why?
|
| Publications | 1 | 2011 | 196 | 0.080 |
Why?
|
| Community Pharmacy Services | 1 | 2009 | 52 | 0.080 |
Why?
|
| Schizophrenia | 2 | 2005 | 6986 | 0.080 |
Why?
|
| Truth Disclosure | 1 | 2013 | 433 | 0.080 |
Why?
|
| Rhabdomyolysis | 1 | 2010 | 152 | 0.080 |
Why?
|
| Health Care Surveys | 4 | 2019 | 2437 | 0.080 |
Why?
|
| Lidocaine | 1 | 2012 | 545 | 0.080 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 1999 | 2145 | 0.080 |
Why?
|
| Beverages | 1 | 1994 | 822 | 0.080 |
Why?
|
| Physician's Role | 4 | 2007 | 927 | 0.080 |
Why?
|
| Long QT Syndrome | 1 | 2013 | 472 | 0.080 |
Why?
|
| Government Agencies | 1 | 2009 | 161 | 0.080 |
Why?
|
| Psychotic Disorders | 2 | 2005 | 3278 | 0.080 |
Why?
|
| Faculty, Medical | 1 | 2017 | 1218 | 0.080 |
Why?
|
| Heart Conduction System | 1 | 1994 | 1009 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 4 | 2007 | 2226 | 0.080 |
Why?
|
| Evidence-Based Practice | 1 | 2012 | 500 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 876 | 0.070 |
Why?
|
| Self Report | 2 | 2019 | 3771 | 0.070 |
Why?
|
| Medical History Taking | 2 | 1991 | 776 | 0.070 |
Why?
|
| Pharmacology, Clinical | 1 | 1987 | 23 | 0.070 |
Why?
|
| Dissent and Disputes | 1 | 2009 | 150 | 0.070 |
Why?
|
| Speech | 1 | 2013 | 558 | 0.070 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2018 | 1189 | 0.070 |
Why?
|
| France | 2 | 2021 | 497 | 0.070 |
Why?
|
| Aspirin | 5 | 2008 | 3139 | 0.070 |
Why?
|
| Cesarean Section | 2 | 2016 | 1414 | 0.070 |
Why?
|
| Hospitals, Teaching | 5 | 2001 | 1158 | 0.070 |
Why?
|
| Delirium | 2 | 2018 | 1694 | 0.070 |
Why?
|
| Germany | 2 | 2016 | 882 | 0.070 |
Why?
|
| Employer Health Costs | 1 | 2006 | 21 | 0.070 |
Why?
|
| Pamphlets | 1 | 2007 | 71 | 0.070 |
Why?
|
| Heparin Antagonists | 1 | 2007 | 34 | 0.070 |
Why?
|
| Seizures | 2 | 2010 | 2996 | 0.070 |
Why?
|
| Mental Health Services | 2 | 2010 | 1732 | 0.070 |
Why?
|
| Hematinics | 1 | 2010 | 282 | 0.070 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 4567 | 0.070 |
Why?
|
| Dementia | 6 | 2017 | 2723 | 0.070 |
Why?
|
| Fluoridation | 1 | 1986 | 29 | 0.070 |
Why?
|
| Double-Blind Method | 4 | 2011 | 12450 | 0.070 |
Why?
|
| Licensure, Medical | 1 | 2007 | 72 | 0.070 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 3 | 2018 | 317 | 0.070 |
Why?
|
| Actuarial Analysis | 1 | 2006 | 372 | 0.070 |
Why?
|
| Antithrombins | 2 | 2021 | 294 | 0.070 |
Why?
|
| Federal Government | 2 | 2022 | 266 | 0.070 |
Why?
|
| Metronidazole | 2 | 2003 | 233 | 0.070 |
Why?
|
| Sulfoxides | 1 | 2006 | 47 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 1997 | 1605 | 0.070 |
Why?
|
| Duty to Warn | 1 | 2006 | 30 | 0.070 |
Why?
|
| Hypoglycemia | 1 | 1994 | 894 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 3 | 2008 | 1193 | 0.070 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2006 | 32 | 0.070 |
Why?
|
| Blood Coagulation | 2 | 2008 | 1162 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 3735 | 0.070 |
Why?
|
| Anti-Infective Agents | 3 | 2018 | 987 | 0.070 |
Why?
|
| Deception | 1 | 2006 | 101 | 0.060 |
Why?
|
| Community-Institutional Relations | 1 | 2007 | 208 | 0.060 |
Why?
|
| Fees and Charges | 1 | 2007 | 192 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 3 | 2007 | 2483 | 0.060 |
Why?
|
| Gout Suppressants | 1 | 2007 | 177 | 0.060 |
Why?
|
| Retreatment | 2 | 2011 | 601 | 0.060 |
Why?
|
| Phosphatidylglycerols | 1 | 2005 | 34 | 0.060 |
Why?
|
| Insurance Benefits | 1 | 2007 | 187 | 0.060 |
Why?
|
| Population Surveillance | 2 | 2011 | 2601 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2009 | 3484 | 0.060 |
Why?
|
| Dextropropoxyphene | 4 | 1987 | 26 | 0.060 |
Why?
|
| Deoxycholic Acid | 1 | 2005 | 54 | 0.060 |
Why?
|
| SEER Program | 2 | 2001 | 1476 | 0.060 |
Why?
|
| Placebos | 2 | 2006 | 1668 | 0.060 |
Why?
|
| Residence Characteristics | 2 | 2012 | 2119 | 0.060 |
Why?
|
| Severity of Illness Index | 7 | 2014 | 15965 | 0.060 |
Why?
|
| Neuralgia | 1 | 2012 | 620 | 0.060 |
Why?
|
| Infant, Newborn | 7 | 2017 | 26395 | 0.060 |
Why?
|
| Amphotericin B | 1 | 2005 | 143 | 0.060 |
Why?
|
| Benzhydryl Compounds | 1 | 2012 | 939 | 0.060 |
Why?
|
| Morbidity | 4 | 1996 | 1760 | 0.060 |
Why?
|
| Factor VII | 1 | 2005 | 139 | 0.060 |
Why?
|
| Knee Joint | 2 | 2004 | 1683 | 0.060 |
Why?
|
| Losartan | 1 | 2006 | 263 | 0.060 |
Why?
|
| Analysis of Variance | 5 | 2007 | 6242 | 0.060 |
Why?
|
| Autoantibodies | 2 | 2005 | 2131 | 0.060 |
Why?
|
| Half-Life | 2 | 2001 | 650 | 0.060 |
Why?
|
| Boston | 5 | 2002 | 9361 | 0.060 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2005 | 187 | 0.060 |
Why?
|
| Abdominal Pain | 1 | 1991 | 1070 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2014 | 1594 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2005 | 275 | 0.060 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2005 | 311 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 1993 | 1389 | 0.060 |
Why?
|
| Pharmacokinetics | 2 | 1996 | 86 | 0.060 |
Why?
|
| Ranitidine | 1 | 2003 | 34 | 0.060 |
Why?
|
| Factor IX | 1 | 2004 | 76 | 0.060 |
Why?
|
| Platelet Transfusion | 1 | 2007 | 301 | 0.060 |
Why?
|
| Clinical Pharmacy Information Systems | 2 | 1996 | 102 | 0.060 |
Why?
|
| Decision Making, Organizational | 1 | 2004 | 136 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2015 | 1876 | 0.060 |
Why?
|
| Violence | 1 | 2010 | 937 | 0.060 |
Why?
|
| Pharmacology | 2 | 1996 | 98 | 0.060 |
Why?
|
| Phosphatidylcholines | 1 | 2005 | 406 | 0.060 |
Why?
|
| Calcium Channel Agonists | 1 | 2003 | 26 | 0.060 |
Why?
|
| Morale | 1 | 1983 | 13 | 0.050 |
Why?
|
| Blood Transfusion | 4 | 2000 | 1308 | 0.050 |
Why?
|
| Continuity of Patient Care | 2 | 2008 | 1076 | 0.050 |
Why?
|
| Public Health Informatics | 1 | 2004 | 109 | 0.050 |
Why?
|
| Cause of Death | 3 | 2012 | 3727 | 0.050 |
Why?
|
| Cannabinoids | 1 | 2005 | 173 | 0.050 |
Why?
|
| Scotland | 1 | 2002 | 143 | 0.050 |
Why?
|
| Infant | 8 | 2017 | 36497 | 0.050 |
Why?
|
| Economics, Hospital | 1 | 1985 | 210 | 0.050 |
Why?
|
| Prevalence | 8 | 2015 | 15880 | 0.050 |
Why?
|
| Ireland | 1 | 2002 | 170 | 0.050 |
Why?
|
| Decision Trees | 2 | 2007 | 510 | 0.050 |
Why?
|
| Life Tables | 1 | 2002 | 368 | 0.050 |
Why?
|
| Software Design | 1 | 2002 | 173 | 0.050 |
Why?
|
| Social Class | 2 | 2001 | 2000 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2014 | 3122 | 0.050 |
Why?
|
| Diabetic Nephropathies | 2 | 2006 | 975 | 0.050 |
Why?
|
| Blood Component Transfusion | 1 | 2003 | 142 | 0.050 |
Why?
|
| Creatinine | 3 | 2007 | 1915 | 0.050 |
Why?
|
| Ethicists | 1 | 1982 | 39 | 0.050 |
Why?
|
| Ethics | 1 | 1982 | 94 | 0.050 |
Why?
|
| Chlorpropamide | 1 | 2001 | 6 | 0.050 |
Why?
|
| Cholesterol | 3 | 2007 | 2910 | 0.050 |
Why?
|
| New York | 3 | 2021 | 882 | 0.050 |
Why?
|
| Child, Preschool | 8 | 2017 | 42623 | 0.050 |
Why?
|
| Program Development | 1 | 2008 | 1296 | 0.050 |
Why?
|
| Philosophy | 1 | 1982 | 69 | 0.050 |
Why?
|
| Amiodarone | 1 | 2003 | 217 | 0.050 |
Why?
|
| Meperidine | 1 | 2001 | 38 | 0.050 |
Why?
|
| Therapies, Investigational | 1 | 2023 | 111 | 0.050 |
Why?
|
| China | 1 | 2008 | 2398 | 0.050 |
Why?
|
| Cooperative Behavior | 2 | 2012 | 1514 | 0.050 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2013 | 1931 | 0.050 |
Why?
|
| Prognosis | 6 | 2008 | 30028 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 1727 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 2007 | 574 | 0.050 |
Why?
|
| Reimbursement Mechanisms | 2 | 2006 | 677 | 0.050 |
Why?
|
| Premature Birth | 1 | 2014 | 1816 | 0.050 |
Why?
|
| Sulfonylurea Compounds | 2 | 2014 | 220 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 11206 | 0.050 |
Why?
|
| Forecasting | 4 | 2020 | 2950 | 0.050 |
Why?
|
| Ceftazidime | 1 | 2001 | 57 | 0.050 |
Why?
|
| Retirement | 1 | 1983 | 198 | 0.050 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2021 | 63 | 0.050 |
Why?
|
| Calcitriol | 1 | 2003 | 303 | 0.050 |
Why?
|
| Hospitals, Veterans | 1 | 2004 | 395 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2005 | 677 | 0.050 |
Why?
|
| Barbiturates | 1 | 2001 | 113 | 0.050 |
Why?
|
| Mental Disorders | 3 | 2014 | 6879 | 0.050 |
Why?
|
| Calibration | 3 | 2010 | 823 | 0.050 |
Why?
|
| Legislation, Medical | 1 | 2021 | 98 | 0.050 |
Why?
|
| Life Expectancy | 3 | 2005 | 1249 | 0.050 |
Why?
|
| Suicide, Attempted | 1 | 2010 | 1409 | 0.050 |
Why?
|
| HIV Infections | 4 | 2023 | 17564 | 0.050 |
Why?
|
| Occupational Health | 1 | 2007 | 814 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2005 | 1889 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2007 | 2731 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2005 | 879 | 0.050 |
Why?
|
| Educational Status | 2 | 2007 | 2519 | 0.040 |
Why?
|
| Prolactin | 1 | 2002 | 626 | 0.040 |
Why?
|
| Survival Rate | 3 | 2016 | 12875 | 0.040 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2003 | 308 | 0.040 |
Why?
|
| Diabetes Complications | 2 | 2015 | 1322 | 0.040 |
Why?
|
| Time | 1 | 2002 | 546 | 0.040 |
Why?
|
| Prospective Studies | 9 | 2012 | 54914 | 0.040 |
Why?
|
| Cephalosporins | 1 | 2001 | 200 | 0.040 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2005 | 1097 | 0.040 |
Why?
|
| Pregnancy Trimester, First | 2 | 2015 | 918 | 0.040 |
Why?
|
| Financial Support | 1 | 2021 | 116 | 0.040 |
Why?
|
| Health | 1 | 1983 | 399 | 0.040 |
Why?
|
| Disability Evaluation | 2 | 2004 | 1839 | 0.040 |
Why?
|
| Social Responsibility | 1 | 2022 | 385 | 0.040 |
Why?
|
| Dibenzothiazepines | 2 | 2012 | 102 | 0.040 |
Why?
|
| Financing, Organized | 1 | 2021 | 206 | 0.040 |
Why?
|
| Vaginal Smears | 1 | 2002 | 501 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2010 | 6278 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2011 | 2347 | 0.040 |
Why?
|
| Guidelines as Topic | 2 | 2012 | 1395 | 0.040 |
Why?
|
| England | 1 | 2020 | 533 | 0.040 |
Why?
|
| Knee Injuries | 1 | 2004 | 495 | 0.040 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2002 | 291 | 0.040 |
Why?
|
| Pediatrics | 1 | 2014 | 3622 | 0.040 |
Why?
|
| Interviews as Topic | 2 | 2005 | 2733 | 0.040 |
Why?
|
| Exfoliation Syndrome | 1 | 2000 | 113 | 0.040 |
Why?
|
| Suicide | 1 | 2010 | 1608 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 2228 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 1183 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 544 | 0.040 |
Why?
|
| Cholestyramine Resin | 1 | 1998 | 25 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2016 | 5192 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2005 | 1820 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2010 | 2526 | 0.040 |
Why?
|
| Home Care Services | 1 | 2005 | 655 | 0.040 |
Why?
|
| Family Practice | 1 | 2001 | 510 | 0.040 |
Why?
|
| Management Information Systems | 2 | 2007 | 49 | 0.040 |
Why?
|
| Epidemiologic Studies | 1 | 2001 | 681 | 0.040 |
Why?
|
| Myocardial Revascularization | 2 | 2013 | 796 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2004 | 937 | 0.040 |
Why?
|
| Social Environment | 1 | 1983 | 1026 | 0.040 |
Why?
|
| Electrocardiography | 3 | 2010 | 6410 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2003 | 1097 | 0.040 |
Why?
|
| Risperidone | 2 | 2012 | 383 | 0.040 |
Why?
|
| Quebec | 1 | 1997 | 139 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2005 | 2206 | 0.040 |
Why?
|
| Low Back Pain | 1 | 2006 | 989 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2000 | 830 | 0.040 |
Why?
|
| Minnesota | 2 | 2009 | 338 | 0.040 |
Why?
|
| Catheterization, Central Venous | 1 | 2002 | 530 | 0.040 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2002 | 959 | 0.030 |
Why?
|
| Population | 1 | 1997 | 141 | 0.030 |
Why?
|
| Troponin I | 1 | 2001 | 662 | 0.030 |
Why?
|
| Health Surveys | 3 | 2019 | 4056 | 0.030 |
Why?
|
| New England | 2 | 1997 | 1056 | 0.030 |
Why?
|
| Substance-Related Disorders | 4 | 2016 | 4453 | 0.030 |
Why?
|
| Single-Blind Method | 2 | 2012 | 1585 | 0.030 |
Why?
|
| Piperidines | 1 | 2005 | 1664 | 0.030 |
Why?
|
| Oxazolidinones | 1 | 2017 | 98 | 0.030 |
Why?
|
| Employment | 1 | 1983 | 1120 | 0.030 |
Why?
|
| Ontario | 1 | 1997 | 403 | 0.030 |
Why?
|
| Stress, Psychological | 2 | 1991 | 4538 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2004 | 7895 | 0.030 |
Why?
|
| Parathyroid Hormone | 1 | 2003 | 1804 | 0.030 |
Why?
|
| Culture | 1 | 2000 | 624 | 0.030 |
Why?
|
| Esters | 1 | 2017 | 212 | 0.030 |
Why?
|
| Demography | 2 | 1993 | 1643 | 0.030 |
Why?
|
| Self Medication | 1 | 1997 | 117 | 0.030 |
Why?
|
| Colorectal Neoplasms | 2 | 2006 | 6978 | 0.030 |
Why?
|
| Motor Activity | 1 | 2006 | 2722 | 0.030 |
Why?
|
| Postmenopause | 1 | 2005 | 2519 | 0.030 |
Why?
|
| Mammography | 2 | 2007 | 2436 | 0.030 |
Why?
|
| Thyroid Diseases | 1 | 1999 | 388 | 0.030 |
Why?
|
| Sulfhydryl Compounds | 1 | 2017 | 298 | 0.030 |
Why?
|
| Disease Management | 2 | 2012 | 2533 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 36840 | 0.030 |
Why?
|
| Michigan | 2 | 1986 | 341 | 0.030 |
Why?
|
| Norway | 1 | 2016 | 501 | 0.030 |
Why?
|
| Reference Values | 1 | 2002 | 4941 | 0.030 |
Why?
|
| Reagent Strips | 1 | 1995 | 40 | 0.030 |
Why?
|
| Training Support | 1 | 2015 | 109 | 0.030 |
Why?
|
| Home Infusion Therapy | 1 | 1995 | 18 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 4572 | 0.030 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1995 | 99 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2017 | 2656 | 0.030 |
Why?
|
| Cephalexin | 2 | 1986 | 37 | 0.030 |
Why?
|
| World Health Organization | 1 | 2021 | 1328 | 0.030 |
Why?
|
| Independent Living | 1 | 2019 | 580 | 0.030 |
Why?
|
| Formularies as Topic | 2 | 2006 | 94 | 0.030 |
Why?
|
| Social Support | 3 | 2002 | 2195 | 0.030 |
Why?
|
| Minority Health | 1 | 2015 | 79 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 1995 | 329 | 0.030 |
Why?
|
| Orthopedic Procedures | 1 | 2004 | 1280 | 0.030 |
Why?
|
| Vaccination | 1 | 2007 | 3434 | 0.030 |
Why?
|
| Uridine Monophosphate | 1 | 2015 | 67 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 853 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2006 | 3590 | 0.030 |
Why?
|
| Amides | 1 | 2017 | 452 | 0.030 |
Why?
|
| HIV Seropositivity | 2 | 1991 | 963 | 0.030 |
Why?
|
| Mastectomy | 1 | 2003 | 1852 | 0.030 |
Why?
|
| Consumer Advocacy | 1 | 1995 | 83 | 0.030 |
Why?
|
| Emergency Service, Hospital | 4 | 2015 | 7956 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2003 | 3550 | 0.030 |
Why?
|
| Poverty Areas | 1 | 2015 | 265 | 0.030 |
Why?
|
| Enema | 1 | 1994 | 141 | 0.030 |
Why?
|
| Obesity | 3 | 2005 | 13065 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2005 | 3246 | 0.030 |
Why?
|
| Mental Status Schedule | 2 | 1991 | 315 | 0.030 |
Why?
|
| Fluorenes | 1 | 2015 | 160 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2001 | 1795 | 0.030 |
Why?
|
| Renin | 1 | 1996 | 642 | 0.030 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 1994 | 165 | 0.030 |
Why?
|
| Carbamates | 1 | 2015 | 192 | 0.030 |
Why?
|
| Valine | 1 | 2015 | 410 | 0.030 |
Why?
|
| Dosage Forms | 1 | 2013 | 56 | 0.030 |
Why?
|
| New Hampshire | 3 | 1991 | 175 | 0.030 |
Why?
|
| Ribavirin | 1 | 2015 | 395 | 0.030 |
Why?
|
| Pyrrolidines | 1 | 2015 | 341 | 0.030 |
Why?
|
| Electronics | 1 | 2014 | 318 | 0.030 |
Why?
|
| Mass Media | 1 | 2016 | 304 | 0.030 |
Why?
|
| Feedback | 2 | 2004 | 794 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2013 | 455 | 0.030 |
Why?
|
| Visual Fields | 1 | 2000 | 1067 | 0.030 |
Why?
|
| Diabetic Retinopathy | 1 | 2002 | 1299 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1997 | 1840 | 0.030 |
Why?
|
| Efficiency | 2 | 2007 | 477 | 0.030 |
Why?
|
| Therapeutic Human Experimentation | 1 | 1992 | 43 | 0.030 |
Why?
|
| MEDLINE | 1 | 1992 | 119 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1999 | 1209 | 0.030 |
Why?
|
| Self Efficacy | 2 | 2008 | 651 | 0.030 |
Why?
|
| Cognition Disorders | 2 | 2005 | 3985 | 0.030 |
Why?
|
| Sex | 1 | 2012 | 53 | 0.030 |
Why?
|
| Bloodletting | 1 | 1992 | 22 | 0.030 |
Why?
|
| Cross Infection | 1 | 1981 | 1425 | 0.030 |
Why?
|
| Education, Nursing, Continuing | 1 | 1992 | 69 | 0.020 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2015 | 295 | 0.020 |
Why?
|
| alpha-Glucosidases | 1 | 2012 | 46 | 0.020 |
Why?
|
| Case Management | 1 | 2014 | 276 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2005 | 4948 | 0.020 |
Why?
|
| Back Pain | 1 | 2016 | 547 | 0.020 |
Why?
|
| Geriatric Psychiatry | 1 | 1992 | 70 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 162 | 0.020 |
Why?
|
| Pulse | 1 | 1992 | 218 | 0.020 |
Why?
|
| Chi-Square Distribution | 2 | 2000 | 3438 | 0.020 |
Why?
|
| Color | 1 | 2013 | 297 | 0.020 |
Why?
|
| Administration, Topical | 1 | 1994 | 707 | 0.020 |
Why?
|
| Urinalysis | 1 | 1994 | 369 | 0.020 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2012 | 123 | 0.020 |
Why?
|
| Vitamin K | 1 | 2014 | 314 | 0.020 |
Why?
|
| Education, Continuing | 1 | 1992 | 114 | 0.020 |
Why?
|
| Models, Biological | 1 | 2008 | 9505 | 0.020 |
Why?
|
| Child Psychiatry | 1 | 2014 | 231 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2000 | 2326 | 0.020 |
Why?
|
| Escherichia coli Infections | 1 | 1995 | 524 | 0.020 |
Why?
|
| Internationality | 1 | 2016 | 1007 | 0.020 |
Why?
|
| Organizational Objectives | 2 | 2004 | 427 | 0.020 |
Why?
|
| Cimetidine | 2 | 1987 | 76 | 0.020 |
Why?
|
| Mental Processes | 1 | 1992 | 247 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2001 | 1668 | 0.020 |
Why?
|
| Methotrexate | 2 | 2008 | 1722 | 0.020 |
Why?
|
| Documentation | 2 | 2004 | 913 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2013 | 423 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 1999 | 1494 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2015 | 909 | 0.020 |
Why?
|
| Glucose | 1 | 2022 | 4355 | 0.020 |
Why?
|
| Electronic Prescribing | 1 | 2011 | 114 | 0.020 |
Why?
|
| Calcium Channel Blockers | 2 | 2006 | 692 | 0.020 |
Why?
|
| Rupture | 1 | 2012 | 444 | 0.020 |
Why?
|
| Angioedema | 1 | 2012 | 184 | 0.020 |
Why?
|
| Health Education | 4 | 1987 | 1059 | 0.020 |
Why?
|
| Quality of Life | 5 | 2009 | 13497 | 0.020 |
Why?
|
| Professional Practice | 2 | 1990 | 314 | 0.020 |
Why?
|
| Haloperidol | 1 | 2012 | 394 | 0.020 |
Why?
|
| Blood Banks | 2 | 1990 | 108 | 0.020 |
Why?
|
| Health Promotion | 1 | 2002 | 2215 | 0.020 |
Why?
|
| Sexual Behavior | 4 | 1995 | 2200 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 9263 | 0.020 |
Why?
|
| Sympathomimetics | 1 | 1990 | 57 | 0.020 |
Why?
|
| Drug Recalls | 1 | 2009 | 20 | 0.020 |
Why?
|
| Premedication | 1 | 1990 | 246 | 0.020 |
Why?
|
| Journal Impact Factor | 1 | 2011 | 154 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2010 | 301 | 0.020 |
Why?
|
| Clinical Audit | 1 | 2009 | 29 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1991 | 617 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2000 | 2589 | 0.020 |
Why?
|
| Achilles Tendon | 1 | 2012 | 181 | 0.020 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 1990 | 91 | 0.020 |
Why?
|
| Infection Control | 2 | 1990 | 985 | 0.020 |
Why?
|
| Deinstitutionalization | 1 | 1989 | 19 | 0.020 |
Why?
|
| Vitamin D | 1 | 2003 | 3311 | 0.020 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2009 | 46 | 0.020 |
Why?
|
| Rehabilitation | 1 | 1990 | 131 | 0.020 |
Why?
|
| Uremia | 1 | 1990 | 202 | 0.020 |
Why?
|
| Intermediate Care Facilities | 1 | 1988 | 12 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2016 | 1965 | 0.020 |
Why?
|
| Patient Care Planning | 2 | 1991 | 904 | 0.020 |
Why?
|
| Imidazoles | 1 | 2015 | 1174 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1995 | 806 | 0.020 |
Why?
|
| Imipramine | 1 | 2008 | 98 | 0.020 |
Why?
|
| Review Literature as Topic | 1 | 2010 | 354 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2009 | 246 | 0.020 |
Why?
|
| Institutionalization | 3 | 1994 | 108 | 0.020 |
Why?
|
| Privacy | 1 | 2010 | 233 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 2863 | 0.020 |
Why?
|
| Mixed Function Oxygenases | 1 | 2009 | 265 | 0.020 |
Why?
|
| Metals | 1 | 2012 | 713 | 0.020 |
Why?
|
| Sulfinpyrazone | 1 | 2007 | 15 | 0.020 |
Why?
|
| Epidemiologic Factors | 1 | 2007 | 36 | 0.020 |
Why?
|
| Counseling | 3 | 2009 | 1548 | 0.020 |
Why?
|
| Cefazolin | 1 | 1988 | 95 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2023 | 12813 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2015 | 1342 | 0.020 |
Why?
|
| Genotype | 2 | 2015 | 13047 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2014 | 1146 | 0.020 |
Why?
|
| Probenecid | 1 | 2007 | 73 | 0.020 |
Why?
|
| Financing, Personal | 2 | 2007 | 310 | 0.020 |
Why?
|
| Posture | 1 | 1992 | 956 | 0.020 |
Why?
|
| Control Groups | 1 | 2007 | 107 | 0.020 |
Why?
|
| Medical Informatics | 1 | 2014 | 737 | 0.020 |
Why?
|
| Etidronic Acid | 1 | 2007 | 63 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2007 | 286 | 0.020 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2008 | 186 | 0.020 |
Why?
|
| Respiration Disorders | 1 | 1990 | 367 | 0.020 |
Why?
|
| Editorial Policies | 1 | 2011 | 459 | 0.020 |
Why?
|
| National Health Programs | 1 | 2010 | 442 | 0.020 |
Why?
|
| Remote Consultation | 1 | 2009 | 242 | 0.020 |
Why?
|
| Vermont | 1 | 1986 | 81 | 0.020 |
Why?
|
| Electronic Health Records | 2 | 2015 | 4877 | 0.020 |
Why?
|
| Arkansas | 1 | 1986 | 59 | 0.020 |
Why?
|
| Hydralazine | 1 | 1986 | 34 | 0.020 |
Why?
|
| Occult Blood | 1 | 2007 | 199 | 0.020 |
Why?
|
| Clinical Competence | 2 | 1993 | 4841 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2009 | 1007 | 0.020 |
Why?
|
| Deltaretrovirus | 1 | 1986 | 162 | 0.020 |
Why?
|
| District of Columbia | 1 | 1986 | 159 | 0.020 |
Why?
|
| Absenteeism | 1 | 2007 | 247 | 0.020 |
Why?
|
| Allopurinol | 1 | 2007 | 198 | 0.020 |
Why?
|
| Fluorides | 1 | 1986 | 134 | 0.020 |
Why?
|
| Alendronate | 1 | 2007 | 174 | 0.020 |
Why?
|
| Calcitonin | 1 | 2007 | 329 | 0.020 |
Why?
|
| Professional Competence | 1 | 1989 | 431 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2012 | 2126 | 0.020 |
Why?
|
| Stroke Volume | 1 | 1999 | 5620 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 475 | 0.020 |
Why?
|
| Hospital Costs | 2 | 2006 | 959 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 1364 | 0.020 |
Why?
|
| Databases, Bibliographic | 1 | 2005 | 130 | 0.020 |
Why?
|
| Water Supply | 1 | 1986 | 204 | 0.020 |
Why?
|
| Program Evaluation | 2 | 2004 | 2508 | 0.020 |
Why?
|
| Hospitals, Psychiatric | 1 | 2006 | 318 | 0.020 |
Why?
|
| Bacterial Vaccines | 1 | 2007 | 400 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 588 | 0.010 |
Why?
|
| Densitometry | 1 | 2004 | 151 | 0.010 |
Why?
|
| Quinolones | 1 | 2007 | 382 | 0.010 |
Why?
|
| Occupations | 1 | 2006 | 519 | 0.010 |
Why?
|
| Hospital Records | 1 | 2004 | 93 | 0.010 |
Why?
|
| Safety | 1 | 2009 | 1159 | 0.010 |
Why?
|
| New York City | 3 | 1993 | 738 | 0.010 |
Why?
|
| Bacteria | 1 | 1995 | 2226 | 0.010 |
Why?
|
| Natural Language Processing | 1 | 2013 | 1197 | 0.010 |
Why?
|
| Neuropsychological Tests | 2 | 1994 | 7134 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2004 | 202 | 0.010 |
Why?
|
| Population Dynamics | 1 | 1986 | 314 | 0.010 |
Why?
|
| Papaverine | 1 | 1983 | 45 | 0.010 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2007 | 399 | 0.010 |
Why?
|
| Plasma | 1 | 2007 | 588 | 0.010 |
Why?
|
| Patient Care Management | 1 | 2006 | 304 | 0.010 |
Why?
|
| Helplessness, Learned | 1 | 1983 | 28 | 0.010 |
Why?
|
| Group Practice | 1 | 2004 | 151 | 0.010 |
Why?
|
| Unnecessary Procedures | 1 | 2007 | 420 | 0.010 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2008 | 937 | 0.010 |
Why?
|
| Migraine Disorders | 1 | 2016 | 1713 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 3 | 1993 | 530 | 0.010 |
Why?
|
| Pilot Projects | 3 | 2012 | 8730 | 0.010 |
Why?
|
| Helping Behavior | 1 | 1982 | 21 | 0.010 |
Why?
|
| Perception | 1 | 2009 | 1207 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2004 | 685 | 0.010 |
Why?
|
| Geriatric Nursing | 1 | 1982 | 39 | 0.010 |
Why?
|
| Angina Pectoris | 1 | 1986 | 960 | 0.010 |
Why?
|
| Education, Pharmacy, Continuing | 1 | 2001 | 3 | 0.010 |
Why?
|
| Fever | 1 | 1989 | 1622 | 0.010 |
Why?
|
| Medicine | 1 | 2010 | 946 | 0.010 |
Why?
|
| Moral Obligations | 1 | 1982 | 91 | 0.010 |
Why?
|
| Patient Identification Systems | 1 | 2001 | 75 | 0.010 |
Why?
|
| Comprehension | 1 | 2007 | 641 | 0.010 |
Why?
|
| Least-Squares Analysis | 2 | 1993 | 368 | 0.010 |
Why?
|
| Peer Review, Health Care | 1 | 2001 | 73 | 0.010 |
Why?
|
| Reference Standards | 1 | 2004 | 1015 | 0.010 |
Why?
|
| Troponin | 1 | 2004 | 534 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2006 | 1262 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1995 | 13026 | 0.010 |
Why?
|
| Computers | 1 | 1982 | 592 | 0.010 |
Why?
|
| Computer Security | 1 | 2001 | 260 | 0.010 |
Why?
|
| Life Style | 2 | 2007 | 3929 | 0.010 |
Why?
|
| Eligibility Determination | 1 | 2003 | 420 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1990 | 4202 | 0.010 |
Why?
|
| General Surgery | 1 | 1990 | 1714 | 0.010 |
Why?
|
| Urticaria | 1 | 2000 | 151 | 0.010 |
Why?
|
| Kinetics | 1 | 1986 | 6348 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2005 | 1128 | 0.010 |
Why?
|
| Health Services | 1 | 2004 | 756 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 1983 | 991 | 0.010 |
Why?
|
| Preventive Medicine | 1 | 2000 | 245 | 0.010 |
Why?
|
| Rheumatology | 1 | 2005 | 619 | 0.010 |
Why?
|
| Personal Satisfaction | 1 | 1983 | 648 | 0.010 |
Why?
|
| Heart Rate | 1 | 2010 | 4218 | 0.010 |
Why?
|
| Physical Examination | 1 | 2004 | 1262 | 0.010 |
Why?
|
| Disease Progression | 1 | 2015 | 13655 | 0.010 |
Why?
|
| ROC Curve | 1 | 2005 | 3624 | 0.010 |
Why?
|
| Piperazines | 1 | 2007 | 2546 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1986 | 2203 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2011 | 5371 | 0.010 |
Why?
|
| Peer Group | 1 | 1982 | 697 | 0.010 |
Why?
|
| Body Weight | 1 | 1987 | 4630 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2007 | 6537 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2009 | 3586 | 0.010 |
Why?
|
| Models, Psychological | 2 | 1993 | 835 | 0.010 |
Why?
|
| Exanthema | 1 | 2000 | 504 | 0.010 |
Why?
|
| HIV-1 | 1 | 1993 | 6966 | 0.010 |
Why?
|
| Defecation | 1 | 1997 | 191 | 0.010 |
Why?
|
| Poverty | 1 | 2007 | 2719 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2006 | 2139 | 0.010 |
Why?
|
| Benchmarking | 1 | 2001 | 1058 | 0.010 |
Why?
|
| Radiography | 1 | 2006 | 6995 | 0.010 |
Why?
|
| Consciousness | 1 | 2000 | 603 | 0.010 |
Why?
|
| Recurrence | 1 | 2007 | 8510 | 0.010 |
Why?
|
| Consensus | 1 | 2004 | 3207 | 0.010 |
Why?
|
| Protein Binding | 1 | 1986 | 9376 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1986 | 3212 | 0.010 |
Why?
|
| Critical Care | 1 | 2007 | 2717 | 0.010 |
Why?
|
| Hospital Bed Capacity, 300 to 499 | 1 | 1993 | 55 | 0.010 |
Why?
|
| Osteoarthritis, Knee | 1 | 2004 | 1252 | 0.010 |
Why?
|
| Tobramycin | 1 | 1993 | 65 | 0.010 |
Why?
|
| Body Mass Index | 2 | 2005 | 13030 | 0.010 |
Why?
|
| Forms and Records Control | 1 | 1993 | 158 | 0.010 |
Why?
|
| Prothrombin Time | 1 | 1992 | 117 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 1982 | 2737 | 0.010 |
Why?
|
| Microcomputers | 1 | 1992 | 140 | 0.010 |
Why?
|
| Swine | 1 | 2002 | 5996 | 0.010 |
Why?
|
| Marital Status | 1 | 1993 | 426 | 0.010 |
Why?
|
| Cefoxitin | 1 | 1990 | 35 | 0.010 |
Why?
|
| Hospitals, Community | 1 | 1993 | 365 | 0.010 |
Why?
|
| Liver | 1 | 1986 | 7575 | 0.010 |
Why?
|
| Psychological Tests | 1 | 1993 | 643 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1990 | 187 | 0.010 |
Why?
|
| Nurse-Patient Relations | 1 | 1990 | 100 | 0.010 |
Why?
|
| Homosexuality | 1 | 1991 | 268 | 0.010 |
Why?
|
| State Health Plans | 1 | 1991 | 220 | 0.010 |
Why?
|
| Systole | 1 | 1992 | 938 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 2260 | 0.010 |
Why?
|
| Electrolytes | 1 | 1990 | 278 | 0.010 |
Why?
|
| Diastole | 1 | 1992 | 784 | 0.010 |
Why?
|
| Adaptation, Psychological | 2 | 1993 | 2665 | 0.000 |
Why?
|
| Behavior Control | 1 | 1988 | 48 | 0.000 |
Why?
|
| Behavioral Research | 1 | 1988 | 52 | 0.000 |
Why?
|
| Pain | 1 | 2003 | 5096 | 0.000 |
Why?
|
| Mentally Ill Persons | 1 | 1988 | 126 | 0.000 |
Why?
|
| Flurazepam | 1 | 1987 | 8 | 0.000 |
Why?
|
| Marriage | 1 | 1988 | 352 | 0.000 |
Why?
|
| Blood Specimen Collection | 1 | 1987 | 238 | 0.000 |
Why?
|
| Behavior | 1 | 1986 | 545 | 0.000 |
Why?
|
| Brain | 1 | 1990 | 27438 | 0.000 |
Why?
|
| Surgical Procedures, Operative | 1 | 1993 | 1937 | 0.000 |
Why?
|
| Alcohol Drinking | 1 | 1994 | 4052 | 0.000 |
Why?
|
| HIV Antibodies | 1 | 1986 | 1341 | 0.000 |
Why?
|
| Exercise | 1 | 1994 | 5940 | 0.000 |
Why?
|
| Fear | 1 | 1986 | 1494 | 0.000 |
Why?
|
| Opium | 1 | 1973 | 28 | 0.000 |
Why?
|
| Social Problems | 1 | 1973 | 109 | 0.000 |
Why?
|
| Heroin Dependence | 1 | 1973 | 175 | 0.000 |
Why?
|
| Animals | 1 | 2002 | 169418 | 0.000 |
Why?
|
| Cannabis | 1 | 1973 | 444 | 0.000 |
Why?
|
| Alcoholism | 1 | 1973 | 1993 | 0.000 |
Why?
|
| Societies, Medical | 1 | 1973 | 3955 | 0.000 |
Why?
|